Spots Global Cancer Trial Database for medulloblastoma
Every month we try and update this database with for medulloblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma | NCT01351870 | Medulloblastoma | Standard Fracti... Hyperfractionat... | 4 Years - 22 Years | Institut Curie | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | NCT04978727 | Medulloblastoma Glioblastoma Mu... Anaplastic Astr... High-grade Astr... Anaplastic Olig... Anaplastic Epen... Ependymoma Diffuse Intrins... | SurVaxM for pat... SurVaxM for pat... SurVaxM for pat... | 1 Year - 21 Years | Pediatric Brain Tumor Consortium | |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | NCT04337177 | Solid Tumors Neuroblastoma Rhabdomyosarcom... Ewing Sarcoma Hepatoblastoma Medulloblastoma | VAL-413 Temozolomide | 1 Year - 30 Years | Valent Technologies, LLC | |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | NCT01125800 | Medulloblastoma Rhabdomyosarcom... Neuroblastoma Hepatoblastoma Glioma Astrocytoma | LDE225 | 12 Months - 18 Years | Novartis | |
| Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | NCT01171469 | Brain Tumor Glioblastoma Medulloblastoma Ependymoma Anaplastic Astr... | Dendritic Cells Imiquimod | - | Masonic Cancer Center, University of Minnesota | |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | NCT05131763 | Hepatocellular ... Glioblastoma Medulloblastoma Colon Cancer | NKG2D-based CAR... | 18 Years - 75 Years | Fudan University | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| Rare CNS Tumors Outcomes &Risk | NCT03251989 | High Grade Meni... Ependymoma Medulloblastoma PNET Primary CNS Sar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Radiation Therapy and Combination Chemotherapy for Medulloblastoma | NCT02681705 | Medulloblastoma | Temozolomide Craniospinal Ra... | 3 Years - 12 Years | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| Natural History of Patients With Brain and Spinal Cord Tumors | NCT00009035 | Astrocytoma Oligodendroglio... Glioblastoma Glioma Anaplastic Glio... | 1 Year - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System | NCT04743310 | Central Nervous... | tozuleristide Canvas imaging ... Surgical resect... | 18 Years - | Cedars-Sinai Medical Center | |
| Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET | NCT00392327 | Anaplastic Medu... Medulloblastoma | Carboplatin Cisplatin Cyclophosphamid... Filgrastim Isotretinoin Laboratory Biom... Quality-of-Life... Radiation Thera... Vincristine Sul... | 3 Years - 21 Years | Children's Oncology Group | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway | NCT01601184 | Histologically ... Activation of t... | vismodegib Temozolomide | 18 Years - | Centre Leon Berard | |
| Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | NCT03936465 | Solid Tumor, Ch... Lymphoma Brain Tumor, Pe... | BMS-986158 BMS-986378 | 1 Year - 21 Years | Dana-Farber Cancer Institute | |
| Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study | NCT05128903 | Brain Tumor Medulloblastoma | [18F]DPA714 | 8 Years - 39 Years | St. Jude Children's Research Hospital | |
| Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | NCT00601003 | Neuroblastoma Medulloblastoma | Nifurtimox Cyclophosphamid... Topotecan | - 21 Years | Milton S. Hershey Medical Center | |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | NCT05382338 | Medulloblastoma | Cisplatin Cyclophosphamid... Lomustine Mesna Quality-of-Life... Radiation Thera... Sodium Thiosulf... Survey Administ... Vincristine | 3 Years - 21 Years | Children's Oncology Group | |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | NCT00994071 | Medulloblastoma Pontine Glioma Ependymoma Astrocytoma PNET | Temozolomide ABT-888 | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | NCT00031590 | Brain Tumors Central Nervous... Medulloblastoma | Cisplatin Cyclophosphamid... Etoposide Lomustine Vincristine Craniospinal Ra... | 3 Years - 30 Years | Children's Hospital of Philadelphia | |
| International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | NCT02066220 | Brain Tumors | Radiotherapy wi... Reduced-intensi... Radiotherapy wi... Maintenance che... WNT-HR < 16 yea... WNT-HR >= 16 ye... Induction Chemo... SHH-TP53 M0 SHH-TP53 M+ (ge... SHH-TP53 (somat... Vinblastin Main... | 3 Years - 21 Years | Universitätsklinikum Hamburg-Eppendorf | |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | NCT05382338 | Medulloblastoma | Cisplatin Cyclophosphamid... Lomustine Mesna Quality-of-Life... Radiation Thera... Sodium Thiosulf... Survey Administ... Vincristine | 3 Years - 21 Years | Children's Oncology Group | |
| Molecular-Guided Therapy for Childhood Cancer | NCT02162732 | Neuroblastoma Medulloblastoma Glioma Ependymoma Choroid Plexus ... Craniopharyngio... Dysembryoplasti... Meningioma Primitive Neuro... Germ Cell Tumor... Rhabdomyosarcom... Non-rhabdomyosa... Ewings Sarcoma Osteosarcoma Wilms Tumor Renal Cell Carc... Malignant Rhabd... Clear Cell Sarc... Liver Tumors | Guided Therapy | 13 Months - 21 Years | Milton S. Hershey Medical Center | |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study | NCT05128903 | Brain Tumor Medulloblastoma | [18F]DPA714 | 8 Years - 39 Years | St. Jude Children's Research Hospital | |
| A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | NCT03734913 | Basal Cell Carc... Medulloblastoma Adenocarcinoma ... Small Cell Lung... Neuroendocrine ... Glioblastoma | ZSP1602 | 18 Years - 75 Years | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | |
| Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas | NCT06323408 | Glioma, Maligna... Embryonal Tumor Medulloblastoma Ependymoma | Tissue, blood, ... | 15 Years - 39 Years | University Hospital Regensburg | |
| Study of Tomotherapy HD in Medulloblastoma | NCT03675230 | Medulloblastoma | Tomotherapy HD 3DCRT | 3 Years - 12 Years | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| An Intermediate Expanded Use Trial of DFMO | NCT03581240 | Neuroblastoma Medulloblastoma Typical Teratoi... Embryonal Tumor... Ependymoblastom... Medulloepitheli... | eflornithine HC... | 0 Years - 30 Years | Milton S. Hershey Medical Center | |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | NCT04696029 | Medulloblastoma | Difluoromethylo... | - 21 Years | Milton S. Hershey Medical Center | |
| Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | NCT03904862 | Medulloblastoma... | CX 4945 | 3 Years - | Pediatric Brain Tumor Consortium | |
| Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma | NCT05057702 | Medulloblastoma Medulloblastoma... Medulloblastoma... | Specialized Tum... | 12 Months - 39 Years | University of California, San Francisco | |
| Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection | NCT05125666 | Ataxia Medulloblastoma | Dual Task Train... Traditional Reg... | 5 Years - 10 Years | Cairo University | |
| High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood | NCT00180791 | Medulloblastoma Brain Tumors Neuroectodermal... | Etoposide, carb... | - 10 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | NCT04541082 | Central Nervous... Glioblastoma Gliosarcoma, Ad... Anaplastic Olig... Anaplastic Astr... Pilocytic Astro... Oligodendroglio... Gliomatosis Cer... Pleomorphic Xan... Anaplastic Pleo... Diffuse Midline... Ependymoma Ependymoma, Ana... Medulloblastoma Teratoid Rhabdo... Neuroectodermal... Neuroectodermal... Anaplastic Meni... Atypical Mening... Choroid Plexus ... Pineal Tumor Diffuse Astrocy... Glial Tumor | ONC206 | 18 Years - | Chimerix | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma | NCT02040376 | Brain Tumor Tre... | Metformin Placebo | 5 Years - 21 Years | The Hospital for Sick Children | |
| Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | NCT01445288 | Diffuse Intrins... PNET Ependymoma Germinoma Medulloblastoma | 1 Month - 21 Years | National Institutes of Health Clinical Center (CC) | ||
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | NCT00601003 | Neuroblastoma Medulloblastoma | Nifurtimox Cyclophosphamid... Topotecan | - 21 Years | Milton S. Hershey Medical Center | |
| Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System | NCT00867178 | Medulloblastoma Pineoblastoma Supratentorial ... | 3-Dimensional C... Carboplatin Cisplatin Cyclophosphamid... Etoposide Phosp... Isotretinoin Laboratory Biom... Peripheral Bloo... Thiotepa Vincristine Sul... Vorinostat | 2 Months - 47 Months | National Cancer Institute (NCI) | |
| Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma | NCT06396481 | GBM DIPG Brain Tumo... Medulloblastoma | Vγ9Vδ2 T cell | 4 Years - | Beijing Tiantan Hospital | |
| A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | NCT01878617 | Medulloblastoma | Craniospinal Ir... Cyclophosphamid... Cisplatin Vincristine Vismodegib Pemetrexed Gemcitabine Aerobic Trainin... Neurocognitive ... | 3 Years - 39 Years | St. Jude Children's Research Hospital | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor | NCT01326104 | Medulloblastoma Neuroectodermal... | TTRNA-xALT TTRNA-DCs | - 30 Years | University of Florida | |
| Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China | NCT05672043 | Medulloblastoma Central Nervous... Ependymoma Germ Cell Tumor Glioma Brain Tumor, Pe... | 0 Years - 18 Years | Beijing Tiantan Hospital | ||
| Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | NCT04661384 | Ependymoma Glioblastoma Medulloblastoma Recurrent Metas... | IL13Ralpha2-spe... | 18 Years - | City of Hope Medical Center | |
| Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | NCT00031590 | Brain Tumors Central Nervous... Medulloblastoma | Cisplatin Cyclophosphamid... Etoposide Lomustine Vincristine Craniospinal Ra... | 3 Years - 30 Years | Children's Hospital of Philadelphia | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | NCT04270461 | Hepatocellular ... Glioblastoma Medulloblastoma Colon Cancer | NKG2D-based CAR... | 18 Years - 75 Years | Jiujiang University Affiliated Hospital | |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Radiation Therapy and Combination Chemotherapy for Medulloblastoma | NCT02681705 | Medulloblastoma | Temozolomide Craniospinal Ra... | 3 Years - 12 Years | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | NCT02644291 | Medulloblastoma Astrocytoma, Gr... Glioblastoma Anaplastic Astr... Brain Stem Neop... Oligodendroblas... Anaplastic Olig... Malignant Gliom... | Mebendazole | 1 Year - 21 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma | NCT03299309 | Recurrent Medul... Recurrent Brain... Malignant Gliom... | PEP-CMV | 3 Years - 35 Years | Duke University | |
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | NCT02624388 | Lymphoma Childhood Lymph... Solid Tumor Childhood Solid... Neuroblastoma Ewing Sarcoma Hodgkin Lymphom... Non-Hodgkin Lym... Rhabdomyosarcom... Soft Tissue Sar... Medulloblastoma Germ Cell Tumor Wilms Tumor Brain Neoplasms Medulloblastoma... Neuroectodermal... | Genistein Placebo | 1 Year - 21 Years | University of Virginia | |
| Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | NCT03273712 | Neuroendocrine ... Meningioma Neuroblastoma Medulloblastoma | 90Y-DOTA tyr3-O... 68Ga-DOTATOC PE... Amino Acids | 6 Months - 90 Years | University of Iowa | |
| A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | NCT03734913 | Basal Cell Carc... Medulloblastoma Adenocarcinoma ... Small Cell Lung... Neuroendocrine ... Glioblastoma | ZSP1602 | 18 Years - 75 Years | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | |
| A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain | NCT01403311 | Glioma | 5-Aminolevuline... | 18 Years - | Legacy Health System | |
| A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors | NCT00001502 | Brain Neoplasms Glioma Medulloblastoma | RMP-7 and carbo... | - | National Institutes of Health Clinical Center (CC) | |
| Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma | NCT02747576 | Medulloblastoma | 12 Years - 30 Years | St. Jude Children's Research Hospital | ||
| A Study of Pemetrexed in Children With Recurrent Cancer | NCT00520936 | Osteosarcoma Medulloblastoma Sarcoma, Ewing'... Neuroblastoma (... Neuroblastoma (... Positive Evalua... Rhabdomyosarcom... Ependymoma Non-brainstem H... | pemetrexed | - 22 Years | Eli Lilly and Company | |
| Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor | NCT01326104 | Medulloblastoma Neuroectodermal... | TTRNA-xALT TTRNA-DCs | - 30 Years | University of Florida | |
| Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | NCT02574728 | Cancer | Sirolimus Celecoxib Etoposide Cyclophosphamid... | 12 Months - 30 Years | Emory University | |
| Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | NCT01171469 | Brain Tumor Glioblastoma Medulloblastoma Ependymoma Anaplastic Astr... | Dendritic Cells Imiquimod | - | Masonic Cancer Center, University of Minnesota | |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System | NCT04743310 | Central Nervous... | tozuleristide Canvas imaging ... Surgical resect... | 18 Years - | Cedars-Sinai Medical Center | |
| Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer | NCT01802567 | Neuroblastoma Medulloblastoma Brain Tumors Rare Tumors | Guided Therapy-... | 13 Months - | Milton S. Hershey Medical Center | |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma | NCT04402073 | Medulloblastoma | Sonidegib Cisplatin Lomustine Vincristine radiotherapy | 15 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | NCT00867568 | Neuroblastoma Medulloblastoma Relapse | TPI 287 | 12 Months - 21 Years | Milton S. Hershey Medical Center | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | NCT01878617 | Medulloblastoma | Craniospinal Ir... Cyclophosphamid... Cisplatin Vincristine Vismodegib Pemetrexed Gemcitabine Aerobic Trainin... Neurocognitive ... | 3 Years - 39 Years | St. Jude Children's Research Hospital | |
| Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors | NCT02905110 | Brain Tumor Rec... | Methotrexate Etoposide Ommaya Reservoi... | 1 Year - 80 Years | The University of Texas Health Science Center, Houston | |
| An Intermediate Expanded Use Trial of DFMO | NCT03581240 | Neuroblastoma Medulloblastoma Typical Teratoi... Embryonal Tumor... Ependymoblastom... Medulloepitheli... | eflornithine HC... | 0 Years - 30 Years | Milton S. Hershey Medical Center | |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | NCT05382338 | Medulloblastoma | Cisplatin Cyclophosphamid... Lomustine Mesna Quality-of-Life... Radiation Thera... Sodium Thiosulf... Survey Administ... Vincristine | 3 Years - 21 Years | Children's Oncology Group | |
| Natural History of Patients With Brain and Spinal Cord Tumors | NCT00009035 | Astrocytoma Oligodendroglio... Glioblastoma Glioma Anaplastic Glio... | 1 Year - 100 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
